Summary
Definition
History and exam
Risk factors
- advanced age
- male sex
- family history
- gene mutations and nucleotide polymorphisms
- cigarette smoking
- occupational and environmental exposures
- gastro-oesophageal reflux
- viral infection
- bacterial infection
- diabetes
Diagnostic investigations
Investigations to consider
- surgical lung biopsy
- bronchoalveolar lavage (BAL)
- trans-bronchial lung biopsy and cryobiopsy
- CRP
- erythrocyte sedimentation rate (ESR)
- anti-nuclear antibody immunofluorescence
- rheumatoid factor
- anti-cyclic citrullinated peptide
- myositis panel
Treatment algorithm
Contributors
Authors
Mary Elizabeth Kreider, MD, MS
Associate Professor of Clinical Medicine
Pulmonary, Allergy, and Critical Care Division
Perelman School of Medicine
University of Pennsylvania
Philadelphia
PA
Disclosures
MEK is serving as site principal investigator for Bellerophon and United Therapeutics for interstitial lung disease (ILD) studies. Her institution receives payments for those trials.
Jake G. Natalini, MD, MS
Assistant Professor of Medicine
Pulmonary, Critical Care, and Sleep Division
NYU Grossman School of Medicine
New York University
New York
NY
Disclosures
JGN is serving as site principal investigator for a CareDx clinical diagnostics study in lung transplantation. His institution receives payments for this trial. He has also previously provided consulting services to CareDx.
Acknowledgements
Dr Mary Elizabeth Kreider and Dr Jake G. Natalini would like to gratefully acknowledge Dr Judd David Flesch, Dr Gregory Tino, and Dr Jeffrey C. Munson, previous contributors to this topic.
Disclosures
GT has served as a consultant for InterMune. GT has served as a principal investigator for clinical trials in idiopathic pulmonary fibrosis. JCM and JDF declare that they have no competing interests.
Peer reviewers
Stephen Nathan, MD
Medical Director
Lung Transplant & Advanced Lung Disease Program
Inova Fairfax Hospital
Falls Church
VA
Disclosures
SN is an author of a reference cited in this monograph.
Athol Wells, MD, FRCP
Professor of Respiratory Medicine
Interstitial Lung Disease Unit
Royal Brompton Hospital
London
UK
Disclosures
AW declares that he has no competing interests.
References
Key articles
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824.Full text Abstract
Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis - an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19.Full text Abstract
Raghu G, Remy-Jardin M, Richeldi L, et al; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47.Full text Abstract
Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. an international working group report. Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75.Full text Abstract
Borie R, Kannengiesser C, Antoniou K, et al. European Respiratory Society statement on familial pulmonary fibrosis. Eur Respir J. 2023 Mar;61(3):2201383.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available here.
Use of this content is subject to our disclaimer